Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 5
2006 4
2007 4
2008 2
2013 1
2014 1
2015 2
2018 1
2019 1
2020 4
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Gener-Ricos G, et al. Among authors: skinner j. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):742-748. doi: 10.1016/j.clml.2023.05.009. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37308342
Long-term results of frontline dasatinib in chronic myeloid leukemia.
Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Maiti A, et al. Among authors: skinner j. Cancer. 2020 Apr 1;126(7):1502-1511. doi: 10.1002/cncr.32627. Epub 2020 Jan 30. Cancer. 2020. PMID: 31999839 Free article. Clinical Trial.
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Jabbour E, et al. Among authors: skinner j. Am J Hematol. 2022 Nov;97(11):1413-1418. doi: 10.1002/ajh.26689. Epub 2022 Aug 27. Am J Hematol. 2022. PMID: 36054032 Free article.
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. Sasaki K, et al. Among authors: skinner j. Am J Hematol. 2021 Feb 1;96(2):241-250. doi: 10.1002/ajh.26047. Epub 2020 Dec 3. Am J Hematol. 2021. PMID: 33180322 Free PMC article. Clinical Trial.
Molecular and structural characterization of barley vernalization genes.
von Zitzewitz J, Szucs P, Dubcovsky J, Yan L, Francia E, Pecchioni N, Casas A, Chen TH, Hayes PM, Skinner JS. von Zitzewitz J, et al. Among authors: skinner js. Plant Mol Biol. 2005 Oct;59(3):449-67. doi: 10.1007/s11103-005-0351-2. Plant Mol Biol. 2005. PMID: 16235110
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Naqvi K, et al. Among authors: skinner j. Cancer. 2020 Jan 1;126(1):67-75. doi: 10.1002/cncr.32504. Epub 2019 Sep 25. Cancer. 2020. PMID: 31553487 Free PMC article. Clinical Trial.
23 results